Clinical trial
Multicenter, Open-label, 12 Week, Phase IV Prospective Randomized Study Aimed at Evaluating Whether sc IFN Beta 1a (Rebif®) Administered in the Morning May Affect the Severity of Flu-like Syndrome and Patient-perceived Invisible Symptoms in Subjects With Relapsing Multiple Sclerosis
NCT02064816 is registered in ClinicalTrials.gov with Merck KGaA, Darmstadt, Germany as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicenter, Open-label, 12 Week, Phase IV Prospective Randomized Study Aimed at Evaluating Whether sc IFN Beta 1a (Rebif®) Administered in the Morning May Affect the Severity of Flu-like Syndrome and Patient-perceived Invisible Symptoms in Subjects With Relapsing Multiple Sclerosis
- Lead sponsor
- Merck KGaA, Darmstadt, Germany
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- May 31, 2014
- Completion date
- April 30, 2016
- Enrollment
- 200 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.